NCT02529956View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Mild to Moderate Psoriasis
Interventions
DRUG

UCB4940

"* Active Substance: UCB4940~* Pharmaceutical Form: Solution for infusion~* Concentration: 80 mg/ml~* Route of Administration: Intravenous use"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Solution for infusion~* Concentration: 0.9 % sodium chloride aqueous solution~* Route of Administration: Intravenous use"

Trial Locations (1)

Unknown

1, Harrow

All Listed Sponsors
lead

UCB Celltech

INDUSTRY

NCT02529956 - A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis | Biotech Hunter | Biotech Hunter